Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937453 · ClinicalTrials.gov registry record
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
A clinical trial of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Nuvance Health.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT03937453: Recruiting study of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Nuvance Health.
NCT03937453 is a study of Pancreatic Cancer and Pancreatic Neoplasms that is actively recruiting participants, run by Nuvance Health. The registered enrollment target is 800 participants, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (105% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03937453, a study of Pancreatic Cancer and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Nuvance Health.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.
Primary Outcome
Determine incidence of pancreatic cancer or precursor lesions in individuals with new-onset diabetes mellitus or deteriorating diabetes
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI/MRCP
Study Locations (1)
Connecticut
- Nuvance Health - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2028-01-19 |
What NCT03937453 shows while recruiting
NCT03937453 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (105% higher).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI/MRCP is the first listed.
NCT03937453 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03937453 about?
NCT03937453 is a clinical study titled "A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus". The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic can...
What is the current status of trial NCT03937453?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2018-01-19. Estimated completion is 2028-01-19.
What conditions does trial NCT03937453 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Neoplasms.
What interventions are being tested in trial NCT03937453?
The interventions under investigation include: MRI/MRCP (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03937453?
This trial is sponsored by Nuvance Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03937453 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03937453's enrollment target sits among peer trials
800 17th of 278 higher than 262 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI